Announced Tue, 16 Jun · 16:30 IST
Zydus completes acquisition of Assertio Holdings at $23.50/share
Compliance View source PDF
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.5%1-day move
₹1079.80
prior close
₹1069.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.1+0.1+0.1-0.5-0.7+0.5+3.0+1.6+4.1+7.5+5.9——
Up moveDown movePending
AI summary
Zydus Lifesciences has completed the cash tender offer to acquire US-based Assertio Holdings (Nasdaq: ASRT) at $23.50 per share through its wholly-owned subsidiary Zara Merger Sub Inc. About 4,28,6488 shares (~66.32% of outstanding) were tendered by June 15, 2026. A merger to acquire remaining shares will be completed on June 16, 2026, after which Assertio will become a wholly-owned subsidiary of Zydus and its shares will be delisted from Nasdaq.
Likely market impact
Expands Zydus's US specialty pharma footprint; Assertio becomes wholly-owned subsidiary, delisted from Nasdaq.